P-glycoprotein-mediated active efflux of the anti-HIV1 nucleoside abacavir limits cellular accumulation and brain distribution
about
Clinical Implications of P-Glycoprotein Modulation in Drug-Drug Interactions.Oral cyclosporin A inhibits CD4 T cell P-glycoprotein activity in HIV-infected adults initiating treatment with nucleoside reverse transcriptase inhibitorsShort-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapyInhibiting drug efflux transporters improves efficacy of ALS therapeuticsAmphiphilic cationic nanogels as brain-targeted carriers for activated nucleoside reverse transcriptase inhibitors.Toward eradicating HIV reservoirs in the brain: inhibiting P-glycoprotein at the blood-brain barrier with prodrug abacavir dimersInduction of P-glycoprotein by antiretroviral drugs in human brain microvessel endothelial cells.Substrate-dependent breast cancer resistance protein (Bcrp1/Abcg2)-mediated interactions: consideration of multiple binding sites in in vitro assay design.Homodimers of the Antiviral Abacavir as Modulators of P-glycoprotein Transport in Cell Culture: Probing Tether Length.Antiretroviral bioanalysis methods of tissues and body biofluids.Drug interactions at the blood-brain barrier: fact or fantasy?Investigation of the micellar effect of pluronic P85 on P-glycoprotein inhibition: cell accumulation and equilibrium dialysis studies.The transport of anti-HIV drugs across blood-CNS interfaces: summary of current knowledge and recommendations for further research.Investigation of the role of breast cancer resistance protein (Bcrp/Abcg2) on pharmacokinetics and central nervous system penetration of abacavir and zidovudine in the mouse.Interactions of tenofovir, Lamivudine, abacavir and Didanosine in primary human cells.Drug transporters: gatekeepers controlling access of xenobiotics to the cellular interior.Drug transporter pharmacogenetics in nucleoside-based therapies.Methadone, buprenorphine, and street drug interactions with antiretroviral medicationsRole of transporters in drug interactions.Pharmacokinetic and pharmacodynamic drug interactions between antiretrovirals and oral contraceptives.Drug transporter gene expression in human colorectal tissue and cell lines: modulation with antiretrovirals for microbicide optimization.Renal Drug Transporters and Drug Interactions.Challenges in the delivery of therapies to melanoma brain metastases.Assessment of P-glycoprotein activity in the Blood-Brain Barrier (BBB) using Near Infrared Fluorescence (NIRF) imaging techniques.The accumulation and metabolism of zidovudine in 3T3-F442A pre-adipocytes.Abacavir transmembrane transportIntranasal administration of antiretroviral-loaded micelles for anatomical targeting to the brain in HIV.Advances in predictive in vitro models of drug-induced nephrotoxicity.Role of ABCB1, ABCG2, ABCC2 and ABCC5 transporters in placental passage of zidovudine.abacavir [cytosol] + ATP + H2O => abacavir[extracellular] + ADP + phosphate_R-HSA-2161517
P2860
Q30234940-88A01524-0520-40C5-8658-6C90E5829FA6Q33864976-55054407-2226-4A84-95DC-4D31F0C4E1BFQ33962223-68BDB074-AA4C-455E-A51D-79C88ECF9D1AQ34824777-8B13FBE4-F4E6-41E5-A055-FD8AF1824D4EQ35108298-76F2D146-DED8-4333-BE8C-53238C0A884EQ35683264-18C5A7BF-2757-4F2F-84D5-853687664785Q37124197-D272F8D6-F425-4052-B844-57E55D987947Q37187988-36934A8C-B5CB-4A4A-88FF-D63AE0840705Q37323391-5F7A51CB-B64C-4E35-AA17-54ABCFF76919Q37332868-2DDAE3A7-493F-4048-BD45-AD614CF33675Q37362486-EC5CFA73-C208-4992-878A-48EA06671135Q37371578-A1975078-5888-4D79-881A-12A3E894BDE8Q37379470-6B091192-3826-418C-86CB-38E54BFDE840Q37387665-9B62503B-B4A2-470B-8482-3B245754FC2CQ37394900-25BF5F4B-C72A-4913-8FCF-ECB5CF65349FQ37514340-B41AB7CA-50DD-487B-9702-CE92FF0FC6C5Q37760954-03743B00-8C3D-4FDA-A222-87A998F93B45Q37763615-17F342A1-CA56-4713-A3BF-F8D61ACA46B3Q37964577-EF6F7076-7CAC-4440-AC19-12D7BF52DD22Q38261574-CFEAF7D4-62F3-4F8C-B118-4342426F4840Q38823939-4A25E9FC-B67C-412D-8480-A5DD4E6D10C0Q39140289-0ADC15FA-FBBF-48AB-B9D7-579006F01E52Q39331752-96305B7F-E253-469F-B86C-8EF949497473Q39539362-AA272B1A-5C24-424D-8D5C-AD4C4D0FE45FQ41811918-F67A746C-1DA0-4FA4-AFC9-3C1173B9B391Q45317527-BFF1C9B5-B1E5-4DCB-86E9-C148F3A734E3Q48284053-F2CFEF00-824B-430F-8052-D6ABA6FDDC1AQ52601626-E5F88653-AC83-46C3-94F6-4EC2E0A08F66Q53816970-12B972F3-E5AC-4E0B-9BBC-1DDCBA58BF65Q56860245-6BEE4DD1-3592-4948-B761-A5E0A83084CC
P2860
P-glycoprotein-mediated active efflux of the anti-HIV1 nucleoside abacavir limits cellular accumulation and brain distribution
description
2007 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 2007
@ast
im November 2007 veröffentlichter wissenschaftlicher Artikel
@de
scientific journal article
@en
vedecký článok (publikovaný 2007/11/01)
@sk
vědecký článek publikovaný v roce 2007
@cs
wetenschappelijk artikel (gepubliceerd op 2007/11/01)
@nl
наукова стаття, опублікована в листопаді 2007
@uk
مقالة علمية نشرت في نوفمبر 2007 حول موضوع: دماغ
@ar
name
P-glycoprotein-mediated active ...... ulation and brain distribution
@ast
P-glycoprotein-mediated active ...... ulation and brain distribution
@en
P-glycoprotein-mediated active ...... ulation and brain distribution
@nl
type
label
P-glycoprotein-mediated active ...... ulation and brain distribution
@ast
P-glycoprotein-mediated active ...... ulation and brain distribution
@en
P-glycoprotein-mediated active ...... ulation and brain distribution
@nl
prefLabel
P-glycoprotein-mediated active ...... ulation and brain distribution
@ast
P-glycoprotein-mediated active ...... ulation and brain distribution
@en
P-glycoprotein-mediated active ...... ulation and brain distribution
@nl
P2093
P356
P1476
P-glycoprotein-mediated active ...... ulation and brain distribution
@en
P2093
Nagdeep Giri
Naveed Shaik
William F. Elmquist
P304
P356
10.1124/DMD.107.017723
P577
2007-11-01T00:00:00Z